NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE236897 Query DataSets for GSE236897
Status Public on Feb 26, 2024
Title Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling [siQ-ChIP]
Organism Homo sapiens
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary DNA methyltransferase inhibitors (DNMTi) are FDA-approved for various hematological malignancies but have limited efficacy in solid tumors. DNA hypomethylation with these drugs is associated with elevated lysine 27 tri-methylation on histone H3 (H3K27me3). We hypothesized that this EZH2-dependent repressive mark limits the full potential of DNMTi. Here, we show in cell line and tumoroid models of colorectal cancer, that low-dose DNMTi sensitizes cells to selective EZH2 inhibitors (EZH2i) that have limited single agent toxicity, and that EZH2i enhances DNMTi-driven molecular and therapeutic effects. Through integrative epigenomic analyses, we reveal that DNMTi induces H3K27me3 accumulation at genomic regions poised with EZH2. Unexpectedly, combined treatment alters the epigenome landscape to promote transcriptional upregulation of the Calcium-Calcineurin-NFAT signaling pathway. Blocking this pathway limits the transcriptional activating effects of the drug combination, including expression of transposable elements and innate immune response genes within a viral defense pathway. Consistently, we demonstrate positive correlations between DNMTi- and viral infection-associated transcription profiles and Calcium signal activation in colon cancer patient samples. Collectively, our study demonstrates that compensatory EZH2 activity following DNA hypomethylation presents a barrier to the therapeutic action of DNMTi in colon cancer, reveals a new application of EZH2i beyond cancers associated with PRC2 hyperactivity, and links Calcium-Calcineurin-NFAT signaling to epigenetic therapy-induced viral mimicry.
 
Overall design Chromatin Immunoprecipitation for H3K27me3 was performed on HCT116 cells treated with: Vehicle (DMSO), 5'aza-2'deoxycytidine (DAC) 30 nM, DAC 300 nM, Tazemetostat (TAZ) (1 uM), or combination DAC + TAZ for 72 hours.
 
Contributor(s) Chomiak AA, Tiedemann RL, Liu Y, Kong X, Cui Y, Thurlow K, Cornett EM, Topper MJ, Baylin SB, Rothbart SB
Citation(s) 38536911
Submission date Jul 10, 2023
Last update date Apr 04, 2024
Contact name Scott Rothbart
E-mail(s) scott.rothbart@vai.org
Organization name Van Andel Research Institute
Street address 333 Bostwick Avenue NE
City Grand Rapids
State/province MI
ZIP/Postal code 49503
Country USA
 
Platforms (2)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (15)
GSM7585012 HCT-116 cells, Veh_H3K27me3_1
GSM7585013 HCT-116 cells, Veh_H3K27me3_2
GSM7585014 HCT-116 cells, DAC30_H3K27me3_1
This SubSeries is part of SuperSeries:
GSE237665 Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling
Relations
BioProject PRJNA993009

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE236897_DAC300_conserved_peaks_Log2FC_all_regions.bed.gz 729.2 Kb (ftp)(http) BED
GSE236897_DAC30_conserved_peaks_Log2FC_all_regions.bed.gz 762.0 Kb (ftp)(http) BED
GSE236897_EPZDAC_conserved_peaks_Log2FC_all_regions.bed.gz 697.9 Kb (ftp)(http) BED
GSE236897_EPZ_conserved_peaks_Log2FC_all_regions.bed.gz 697.1 Kb (ftp)(http) BED
GSE236897_RAW.tar 2.4 Gb (http)(custom) TAR (of BW)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap